Genentech's Petrelintide Phase II Data Show Promising Weight Loss
Event summary
- Genentech announced positive topline results from the Phase II ZUPREME-1 trial for petrelintide, an amylin analog for overweight and obesity.
- The trial, involving 493 participants with a mean BMI of 37 kg/m², met its primary endpoint, demonstrating statistically significant weight loss across all treatment arms compared to placebo.
- Participants achieved up to 10.7% mean weight loss from baseline after 28 weeks, sustained through week 42.
- Female participants experienced considerably more weight loss than male participants in the trial.
The big picture
The obesity treatment market is poised for significant growth, driven by rising global prevalence and increasing demand for effective therapies. Genentech's petrelintide, targeting amylin receptors, represents a novel approach distinct from existing GLP-1 receptor agonists, potentially offering a differentiated option. The collaboration with Zealand Pharma provides Genentech with a valuable asset in this expanding market, but success hinges on demonstrating sustained efficacy and safety in Phase III trials.
What we're watching
- Gender Disparity
- The significant difference in weight loss between female and male participants warrants further investigation to understand the underlying biological mechanisms and inform dosing strategies in future trials.
- Regulatory Path
- The favorable tolerability profile will be critical in navigating regulatory approval, but the FDA and EMA will likely scrutinize the gender-specific efficacy data closely.
- Combo Potential
- The planned Phase II trial combining petrelintide with CT-388 will reveal whether synergistic effects can further enhance efficacy and broaden the therapeutic application.
Related topics